Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of darolutamide in androgen receptor-positive salivary gland carcinoma (Discovary study)
jRCT2031190241Phase 2Completed
- Sponsor
- Bayer
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of darolutamide in salivary gland cancer (SGC), salivary duct carcinoma (SDC), Salivary gland adenocarcinoma (SGAC) and 1 more (2 arms), sponsored by Bayer. Started Apr 2020; status: completed.
02
Drugs
darolutamide
03
Conditions
salivary gland cancer (SGC)salivary duct carcinoma (SDC)Salivary gland adenocarcinoma (SGAC)Carcinoma Ex Pleomorphic Adenoma (CXPA)
Beyond the preview
Go deeper on jRCT2031190241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190241.